Cryo-Cell International
Cryo-Cell International is the world's first private cord blood bank, founded in 1989, offering cryopreservation of umbilical cord blood and cord tissue stem cells for over 500,000 parents across 87 countries. Revenue is generated primarily through subscription-based processing and annual storage fees, with auxiliary biotech R&D through Duke University and USF partnerships.
- Company typePublic
- Founded1989
- HeadquartersOldsmar, United States
- Headcount51–100
- GTM typeB2C
- OfferingServices
Cryo-Cell International firmographics
Firmographics- Name
- Cryo-Cell International
- Legal name
- Cryo-Cell International, Inc.
- Website
- https://cryo-cell.com
- Company type
- Public
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Cryo-Cell International is the world's first private cord blood bank, founded in 1989, offering cryopreservation of umbilical cord blood and cord tissue stem cells for over 500,000 parents across 87 countries. Revenue is generated primarily through subscription-based processing and annual storage fees, with auxiliary biotech R&D through Duke University and USF partnerships.
- Ownership category
- akta.pro rank
Cryo-Cell International industry classification
Industry- Product category
- Stem Cell Banking Services
- NAICS
- Blood and Organ Banks (621991)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)
- akta.pro secondary industries
- Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats) (HLAGAIAJ), Cold Chain Storage & Cryopreservation Services (LN2/Ultra-low) (HLAGAGAK), Transfusion Medicine & Immunohematology (Blood Bank) (HLAFAMAG), Blood, Organ & Tissue Donation Organizations (BPAGACAJ)
Keywords
Where Cryo-Cell International is headquartered
LocationHeadquarters
- HQ city
- Oldsmar
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Cryo-Cell International business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Operations, Personnel, Marketing or Sales, Infrastructure, Technology or R&D
Revenue model
- Processing and Storage Fees: Cryo-Cell charges expectant parents one-time processing fees and recurring annual storage fees for the cryopreservation of cord blood and cord tissue stem cells. Revenue from processing and storage fees constituted $31.4 million of the company's $31.6 million in consolidated fiscal 2025 revenue.
- Public Banking Revenue: Revenue generated from public cord blood banking services, representing $130,000 of consolidated fiscal 2025 revenue.
- Product Revenue: Revenue from product sales related to cord blood and cord tissue banking services, representing $54,000 of consolidated fiscal 2025 revenue.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Cord blood and cord tissue banking with financing and discount options |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Cryo-Cell International product offering
Product offeringCore offering
Cryo-Cell International provides private cord blood and cord tissue banking services, collecting, processing, and cryopreserving newborn umbilical cord blood and tissue stem cells for family use. The company also offers the CéElle menstrual stem cell service and bundled plans (U-Cord Plus, P3 Protect). Revenue is generated primarily from one-time processing fees and recurring annual storage fees for cryogenic preservation in cGMP/cGTP-compliant facilities.
Product overview
Cryo-Cell International operates as a private cord blood bank offering a portfolio of stem cell preservation services. The core offerings include Cord Blood Banking and Cord Tissue Banking, which can be purchased separately or combined through U-Cord Plus. The company also provides Célle, the world's first menstrual stem cell banking service, and the P3 Protect Baby, Protect Mom, Protect Family plan that bundles multiple services. Supporting products include PrepaCyte-CB premium processing technology, the Advanced Collection Kit with enhanced temperature protection, and the 5-Chamber Cord Blood Cryo-Bag for multi-use storage. Educational services such as webinars and a video center support customer onboarding.
Differentiator
Problem solved
Functional benefit
Brands
- Célle: World's first commercial service allowing women to cryopreserve their own menstrual stem cells, launched November 2007
- U-Cord Plus
- P3 Protect Baby, Protect Mom, Protect Family
Products and services
- Cord Blood Banking Primary service collecting, processing, and cryopreserving umbilical cord blood stem cells for private family banking. Marketed to expectant parents for potential future therapeutic use against 80+ FDA-approved conditions.
- Cord Tissue Banking Service for cryopreserving umbilical cord tissue, a rich source of mesenchymal stem cells (MSCs) used in regenerative medicine research for conditions including heart disease, stroke, multiple sclerosis, and diabetes.
- CéElle Menstrual Stem Cell Service World's first commercial service allowing women to cryopreserve their own menstrual stem cells, which can differentiate into many cell types including cardiac and neural cells.
- U-Cord Plus Advanced bundled service combining Cryo-Cell's signature U-Cord cord blood product with cord tissue storage, providing families with multiple stem cell preservation options from a single birth.
- P3 Protect Baby, Protect Mom, Protect Family Exclusive family healthcare protection plan combining U-Cord Plus (cord blood plus cord tissue) with the CéElle menstrual stem cell service, designed to extend healthcare protection across the family.
Quantifiable outcome
- 100% of client collections have been successfully viable upon thaw since inception
- +3 more outcomes
Companies that use Cryo-Cell International
Customer profileNamed customers8 records
Segments2 records
Ideal customer profiles2 records
Cryo-Cell International technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Cryo-Cell International partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- University of South Florida (USF)coreCryo-Cell collaborates with USF's Department of Neurosurgery and Brain Repair on research into the therapeutic potential of cord blood stem cells for neurodegenerative diseases including stroke, Alzheimer's disease, and ALS. Research is conducted through Saneron CCEL Therapeutics, a Cryo-Cell affiliate. Dr. Paul Sanberg and Dr. Cesar Borlongan are key researchers involved in this partnership.
- Cell PRAXIS BioengenhariaminorCell PRAXIS Bioengenharia is a Brazilian platform corporation dedicated to translating research into viable therapeutic tools for regenerative medicine. The company collaborated with Cryo-Cell and USF on a published paper outlining the potential benefits of transplanting umbilical cord and menstrual blood-derived stem cells.
- Duke UniversitycoreCryo-Cell entered into an exclusive license agreement with Duke University granting rights to proprietary processes and regulatory data related to cord blood and cord tissue developed at Duke. The company also holds a patent option agreement with Duke effective June 9, 2020, for Dr. Joanne Kurtzberg's patents. Duke University researchers including Dr. Joanne Kurtzberg are conducting clinical trials using cord blood for conditions such as autism and cerebral palsy.
- Saneron CCEL Therapeutics, Inc.coreSaneron CCEL Therapeutics is a biotechnology R&D company and Cryo-Cell affiliate focused on neurological and cardiac cell therapy. Saneron holds patented and patent-pending technology relating to umbilical cord blood and Sertoli cells, developed in partnership with USF. The company is located at the Tampa Bay Technology Incubator and is committed to providing readily available, non-controversial stem cells for cellular therapies.
Scale indicators7 records
Recent moves9 records
Expansion highlights4 records
Cryo-Cell International competitors and assessment
Company assessmentBroad incumbents
- Cryoport: Specialized cryogenic logistics and cold-chain provider for life sciences, including cell and gene therapies. Comparable to Cryo-Cell's cryopreservation infrastructure capability though operating upstream as a logistics vendor rather than a consumer cord blood bank.
- Chart Industries (Cryogenic Technologies): Industrial cryogenic equipment manufacturer (including MVE biological storage and BioMed services) supplying LN2 storage and handling infrastructure used by biobanks and cell therapy companies. Adjacent infrastructure peer to Cryo-Cell's storage operations.
Direct peers
- Americord Registry: U.S.-based private cord blood, cord tissue, and placental tissue bank targeting the same expectant-parent segment. Competes directly with Cryo-Cell on price, processing technology, and bundle offerings.
- StemCyte: Hybrid public/private cord blood bank with operations in the U.S. and internationally. Overlaps with Cryo-Cell on private family banking and uses similar FDA, AABB, and FACT accreditation frameworks.
- Cord Blood Registry (CBR): One of the largest U.S. private cord blood banks (operated by CooperCompanies), offering umbilical cord blood and cord tissue storage to expectant parents. Direct competitor to Cryo-Cell in the same consumer-driven private banking category with similar accreditation and physician-referral channels.
- LifebankUSA (Cell Care Therapeutics): Canadian-based private cord blood, cord tissue, and placental stem cell bank serving North American families. A direct competitor to Cryo-Cell with similar consumer marketing and recurring storage revenue model.
- ViaCord: Long-standing U.S. private cord blood and cord tissue bank owned by Revvity (formerly PerkinElmer). Competes head-to-head with Cryo-Cell on expectant-parent enrollment, processing technology differentiation, and recurring storage revenue.
Emerging players
- Cesca Therapeutics (now part of Restem): Cell therapy company historically focused on autologous cord blood-derived treatments, particularly for hematologic and autoimmune indications. Adjacent cell therapy peer reflecting the regenerative-medicine vertical Cryo-Cell aims to monetize through its Duke and Saneron relationships.
- BioLife Solutions: Supplier of biopreservation media, cryopreservation equipment, and cold-chain consumables used by cell and gene therapy developers and biobanks. An enabling/adjacent player to Cryo-Cell's cryopreservation operations rather than a direct consumer competitor.
Regional players
- CryoHoldco / Cord Blood Banking Industry Peers: Cluster of smaller U.S. and European private cord blood banks competing in regional and price-sensitive segments. Comparable in core service but typically smaller scale and weaker accreditation stack than Cryo-Cell.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Cryo-Cell International social profiles
Digital presenceCryo-Cell International compliance and trust
Trust signalCompliance7 records
Cryo-Cell International financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cryo-Cell International leadership team
Management profileNumber of profiles
Profiles3 records
Cryo-Cell International subsidiaries and ownership
Company hierarchySubsidiaries1 record
Cryo-Cell International funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cryo-Cell International M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cryo-Cell International
What does Cryo-Cell International do?
Cryo-Cell International provides private cord blood and cord tissue banking services, collecting, processing, and cryopreserving newborn umbilical cord blood and tissue stem cells for family use. The company also offers the CéElle menstrual stem cell service and bundled plans (U-Cord Plus, P3 Protect). Revenue is generated primarily from one-time processing fees and recurring annual storage fees for cryogenic preservation in cGMP/cGTP-compliant facilities.
Is Cryo-Cell International a public or private company?
Cryo-Cell International is a public company. It is classified as public and is currently operating.
When was Cryo-Cell International founded?
Cryo-Cell International was founded in 1989. It employs 51 to 100 people.
Where is Cryo-Cell International based?
Cryo-Cell International is headquartered in Oldsmar, United States, in the North America region.
How does Cryo-Cell International make money?
Three revenue lines are on record. Processing and Storage Fees are the primary driver. The others are public Banking Revenue and product Revenue.
Who are Cryo-Cell International's main competitors?
Broad incumbents on record are Cryoport and Chart Industries (Cryogenic Technologies). Direct peers are Americord Registry, StemCyte, Cord Blood Registry (CBR), LifebankUSA (Cell Care Therapeutics) and ViaCord. Emerging players are Cesca Therapeutics (now part of Restem) and BioLife Solutions. CryoHoldco / Cord Blood Banking Industry Peers is listed as a regional player.
Does Cryo-Cell International have an API?
No public API is recorded for Cryo-Cell International.
What industry is Cryo-Cell International in?
Cryo-Cell International's product category is Stem Cell Banking Services. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue), with a secondary code of HLAGAIAJ, Sample Preparation, Storage & Cryogenics (Freezers, Cryovials, Cryostats). Its NAICS code is 621991 and its SIC code is 2836.